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Coagulation, fibrinolysis, and cell
activation in patients and in shed
mediastinal blood during coronary
artery bypass grafting with a new
heparin-coated surface
To the Editor:
Johnell and colleagues1 recently reported
the improved biocompatibility of a new
heparin-coated surface. They also pre-
sented results after modifications of the an-
ticoagulation protocol. They concluded
that a low dose of systemic heparin might
not be sufficient to maintain the antithrom-
botic activity and that a high dose resulted
in increased blood activation.
The design of the study merits discus-
sion; otherwise, the conclusion might be
misunderstood. In particular, the reduction
of anticoagulation, even combined with a
thromboresistant extracorporeal circuit,
might appear detrimental for patients un-
dergoing cardiopulmonary bypass (CPB).
The basis for a safe low anticoagulation
protocol in combination with heparin-
coated CPB circuits was described by Al-
dea and associates2 in 1998. It includes
many parameters derived from the scien-
tific literature from the 1990s, such as con-
trolled suction with cell-saving devices al-
lowing washing before retransfusion,
limitation of air-blood contact with closed
circuits, specifically adapted anticoagula-
tion through precise heparin and protamine
titration, low prime volume facilitated by
retrograde autologous prime, and normo-
thermia. This tailored approach of CPB,
adopted by our own center, has been found
clinically beneficial3 and is therefore justi-
fied for routine surgical practice. One of the
most important parameters omitted by the
authors in the management of a low hepa-
rinized CPB is the retransfusion of highly
activated blood into the circulation because
cardiotomy suction has been used. The
contact of blood with air or with the surgi-
cal field through the tissue pathway is fol-
lowed by activation of inflammation and
hemostasis disturbances, despite the use of
a significant amount of fluid heparin, which
appears to be an unperfected anticoagulant
for CPB although it is universally used.
When a cell-saving device is used instead
of cardiotomy suction, all the different
markers of blood activation are excluded
and not retransfused into the circulation.
With this approach, it has been proved that
circulating F12 levels do not correlate
with activated clotting time (the lowest ac-
tivated clotting time does not imply the
highest F12) and that a low anticoagulation
protocol is safe for the patient.2 Therefore
some of the results presented by Johnell and
colleagues1 need to be taken with caution.
On the other hand, the study of Johnell
and colleagues1 provides important data
about the detrimental effects of heparin,
which could justify a low anticoagulation
protocol. Evidence of proinflammatory and
procoagulant effects of high-dose heparin
was found, as in previous reports. The re-
duction of heparin dose during CPB with
heparin-coated circuits reduces leukocyte
adhesion on artificial surfaces4 and better
preserves antithrombin III levels.5 In addi-
tion, low anticoagulation requires a low
dose of protamine for titration and reduces
the amount of heparin-protamine com-
plexes known to activate the classic path-
way of complement cascade.
The biocompatibility of new equipment
must be assessed, particularly with respect
to thromboresistance. Johnell and col-
leagues1 successfully demonstrated the re-
duction of contact activation. However, it
is fundamental that the experimental design
respect some principles that have been pre-
viously elucidated when they are expected
to be of major importance in the outcome.
This is particularly true if CPB is managed
with low anticoagulation.
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Myogenesis after myocardial stem
cell transplantation
To the Editor:
I read the article of Chedrawy and col-
leagues,1 “Incorporation and Integration of
Implanted Myogenic and Stem Cells Into
Native Myocardial Fibers: Anatomic Basis
for Functional Improvements,” in the Jour-
nal with great interest. Chedrawy and col-
leagues1 described regenerated isogenic
myofebrile grafts injected into nonischemic
normal myocardium. By 4 to 6 weeks, fully
differentiated myocytes could be seen to
interconnect among native cardiomyo-
cytes. The authors attributed this desirable
incorporation to cell-cell electromechanical
junction. However, in a clinical setting
with scar tissue and akinetic ventricular
wall, the microenvironment is not condu-
cive to electromechanical activity to induce
a desirable environment to trigger pheno-
typic changes for transplanted cells. Is it
possible that cytokines, such as transform-
ing growth factor  or insulin growth fac-
tor, generated because of the presence of
macrophage and monocytes, play a role in
the genesis of proliferation and transforma-
tion of new myofibrils?
Syde Taheri, MD
9095 Main St
Suite C
Clarence, NY 14031
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